FDA 仿制药办公室科学与研究项目及 2026 年研讨会安排
Science & Research | Generic Drugs
FDA 仿制药办公室下属研究与标准办公室依托 GDUFA 设立的科学与研究项目,与业界和公众合作制定仿制药监管科学年度倡议清单,研究成果用于评估仿制药等效性并支持企业开发仿制药。页面列出研究重点与项目、指南与报告,并公布 2026 年 8 月至 12 月的多场研讨会,涉及长效注射剂、吸入制剂、GLP-1 仿制药路径、局部及透皮制剂生物等效性等主题。
The Office of Research and Standards, within the FDA's Office of Generic Drugs (OGD), supports the Science and Research program established under the Generic Drug User Fee Amendments (GDUFA). In collaboration with industry and the public, FDA creates an annual list of regulatory science initiatives on generic drugs. The research studies conducted under these initiatives advance public health by contributing to the development of safe and effective generic drugs. The results provide new tools for FDA to evaluate generic drug equivalence and for industry to efficiently develop new generic products.
Priorities & Projects
Learn more about FDA generic drug research priorities, public workshops, and awarded projects.
Guidances & Reports
View FDA generic drug research publications, including product-specific guidances and annual reports.
Latest Science & Research News
- FDA/Center for Research on Complex Generics (CRCG) Workshop on Long-Acting Injectable (LAI) Generics: Advancing Innovation in Product Development and Regulatory Assessment
Dates: December 1-2, 2026
Register - Advancing Bioequivalence Frameworks for Inhalation Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods
Dates: October 14-15, 2026 - FDA and the Center for Research on Complex Generics (CRCG) Workshop on Navigating the GLP-1 Generic Drug Pathway
Dates: September 23-24, 2026 - Advancing Generic Drug Development (AGDD) Virtual Workshop on Modernizing Bioequivalence Approaches for Topical & Transdermal Products
Date: September 10, 2026 - Advancing Generic Drug Development (AGDD) Virtual Workshop on Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Generic Drugs
Date: August 27, 2026
来源:FDA 官方药品与生物制品信息 · fda.gov